PE20090825A1 - Estratrienos 8-beta-sustituidos como estrogenos de accion selectiva - Google Patents

Estratrienos 8-beta-sustituidos como estrogenos de accion selectiva

Info

Publication number
PE20090825A1
PE20090825A1 PE2008001165A PE2008001165A PE20090825A1 PE 20090825 A1 PE20090825 A1 PE 20090825A1 PE 2008001165 A PE2008001165 A PE 2008001165A PE 2008001165 A PE2008001165 A PE 2008001165A PE 20090825 A1 PE20090825 A1 PE 20090825A1
Authority
PE
Peru
Prior art keywords
estra
8beta
trien
diol
fluoro
Prior art date
Application number
PE2008001165A
Other languages
English (en)
Inventor
Olaf Peters
Nico Brauer
Ina Thieme
Katja Prelle
Peter Muhn
Karl-Heinrich Fritzemeier
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PE20090825A1 publication Critical patent/PE20090825A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0062—Estrane derivatives substituted in position 17 alfa not substituted in position 17 beta

Abstract

REFERIDA A UN DERIVADO ESTRA-1,3,5(10)-TRIENO DE FORMULA (I), DONDE R3 ES H O R18; R18 ES ALQUILO C1-C6, TRIFLUOROMETILO, ENTRE OTROS; R8 ES ALQUENILO C2-C6, ALQUINILO C2-C6 OPCIONALMENTE PARCIAL O COMPLETAMENTE FLUORADOS; R13 ES METILO O ETILO; R16 ES UN ATOMO DE FLUOR; R17 Y R17' SON H, OH, R20SO2-, ENTRE OTROS; R20 ES IGUAL QUE R3. SON COMPUESTOS PREFERIDOS: 8BETA-VINIL-16ALFA-FLUORO-ESTRA-1,3,5(10)-TRIEN-3,17ALFA-DIOL, 8BETA-VINIL-16ALFA-FLUORO-ESTRA-1,3,5(10)-TRIEN-3,17BETA-DIOL, 8BETA-VINIL-16BETA-FLUORO-ESTRA-1,3,5(10)-TRIEN-3,17BETA-DIOL. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS TIENEN ACTIVIDAD SELECTIVA SOBRE LOS RECEPTORES DE ESTROGENO Y SON UTILES EN EL TRATAMIENTO DE TRANSTORNOS DE FERTILIDAD, TERAPIAS DE HIPERPLASIAS, ENTRE OTRAS
PE2008001165A 2007-07-12 2008-07-11 Estratrienos 8-beta-sustituidos como estrogenos de accion selectiva PE20090825A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07075600A EP2014672A1 (en) 2007-07-12 2007-07-12 8-beta-substituted estratrienes as selectively active estrogens

Publications (1)

Publication Number Publication Date
PE20090825A1 true PE20090825A1 (es) 2009-07-25

Family

ID=38657613

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001165A PE20090825A1 (es) 2007-07-12 2008-07-11 Estratrienos 8-beta-sustituidos como estrogenos de accion selectiva

Country Status (34)

Country Link
US (1) US20090029957A1 (es)
EP (2) EP2014672A1 (es)
JP (1) JP2010533152A (es)
KR (1) KR20100037593A (es)
CN (1) CN101687902B (es)
AR (1) AR067507A1 (es)
AU (1) AU2008274198A1 (es)
BR (1) BRPI0814207A2 (es)
CA (1) CA2692727A1 (es)
CL (1) CL2008002027A1 (es)
CO (1) CO6270230A2 (es)
CR (1) CR11211A (es)
CU (1) CU23885B1 (es)
CY (1) CY1113351T1 (es)
DK (1) DK2176282T3 (es)
DO (1) DOP2010000017A (es)
EA (1) EA017124B1 (es)
EC (1) ECSP109872A (es)
ES (1) ES2393942T3 (es)
HN (1) HN2010000081A (es)
HR (1) HRP20120952T1 (es)
MA (1) MA31565B1 (es)
NZ (1) NZ582490A (es)
PA (1) PA8789401A1 (es)
PE (1) PE20090825A1 (es)
PL (1) PL2176282T3 (es)
PT (1) PT2176282E (es)
RS (1) RS52541B (es)
SI (1) SI2176282T1 (es)
TN (1) TN2010000007A1 (es)
TW (1) TW200911824A (es)
UA (1) UA99918C2 (es)
UY (1) UY31220A1 (es)
WO (1) WO2009007454A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2830984C (en) * 2011-03-25 2020-02-11 Universite Laval Inhibitors of 17.beta.-hsd1, 17.beta.-hsd3 and 17.beta.-hsd10.
US10744439B2 (en) * 2016-06-24 2020-08-18 K&N Engineering, Inc. Compound air filter and method of removing airborne molecular contaminants and volatile organic compounds therefrom
USD905747S1 (en) 2018-04-09 2020-12-22 Mitsubishi Electric Corporation Display screen with animated graphical user interface

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10019167A1 (de) * 2000-04-12 2001-10-18 Schering Ag Substituierte Estratriene als selektiv wirksame Estrogene
AU2001258341B2 (en) * 2000-04-12 2007-03-15 Schering Aktiengesellschaft 8beta-hydrocarbyl-substituted estratrienes for use as selective estrogens

Also Published As

Publication number Publication date
EA201000097A1 (ru) 2010-08-30
PA8789401A1 (es) 2009-04-23
TW200911824A (en) 2009-03-16
SI2176282T1 (sl) 2013-02-28
CN101687902B (zh) 2013-07-24
WO2009007454A2 (en) 2009-01-15
EA017124B1 (ru) 2012-10-30
EP2176282B1 (en) 2012-08-22
HRP20120952T1 (hr) 2012-12-31
CA2692727A1 (en) 2009-01-15
NZ582490A (en) 2012-03-30
WO2009007454A3 (en) 2009-03-05
CO6270230A2 (es) 2011-04-20
DK2176282T3 (da) 2012-12-03
JP2010533152A (ja) 2010-10-21
RS52541B (en) 2013-04-30
AR067507A1 (es) 2009-10-14
DOP2010000017A (es) 2010-01-31
CL2008002027A1 (es) 2009-01-16
CU23885B1 (es) 2013-04-19
ES2393942T3 (es) 2013-01-02
AU2008274198A1 (en) 2009-01-15
EP2014672A1 (en) 2009-01-14
PL2176282T3 (pl) 2013-06-28
MA31565B1 (fr) 2010-08-02
CR11211A (es) 2010-04-27
KR20100037593A (ko) 2010-04-09
TN2010000007A1 (en) 2011-09-26
BRPI0814207A2 (pt) 2015-01-27
CY1113351T1 (el) 2016-06-22
UY31220A1 (es) 2009-03-02
PT2176282E (pt) 2012-11-30
ECSP109872A (es) 2010-02-26
HN2010000081A (es) 2013-07-01
EP2176282A2 (en) 2010-04-21
CN101687902A (zh) 2010-03-31
US20090029957A1 (en) 2009-01-29
CU20100008A7 (es) 2011-05-27
UA99918C2 (ru) 2012-10-25

Similar Documents

Publication Publication Date Title
UA86957C2 (ru) Производные азепиноиндола в качестве фармацевтического средства
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
ECSP099452A (es) Derivados de éster y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides
BRPI0607523A2 (pt) compostos esteróides de heteroarila c-17, composições farmacêuticas compreendendo os mesmos e uso dos referidos compostos na preparação de medicamentos
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
TW200619202A (en) Indazoles, benzisoxazoles and benzisothiazoles, process for preparing them, pharmaceutical compositions and use as estrogenic agents
MX2009012613A (es) Tiazoles substituidos por heteroarilo y su uso como agentes antivirales.
PE20141554A1 (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparacion, preparados farmaceuticos que los contienen, asi como su uso para la preparacion de medicamentos
PE20080995A1 (es) 18-metil-19-nor-androst-4-en-17,17-espiroeteres(18-metil-19-nor-20-espirox-4-en-3-onas), asi como preparaciones farmaceuticas que los contienen
ECSP099425A (es) Derivados de amina y su uso en enfermedades mediadas por el adrenorecetor beta 2
PE20090825A1 (es) Estratrienos 8-beta-sustituidos como estrogenos de accion selectiva
NO20065885L (no) Steroide prolegemidler med androgen virkning
ECSP055530A (es) Estratrienos 9-alfa-sustituidos como estrógenos de eficacia selectiva
AR071721A1 (es) Derivados de piridil-prolinamida, composiciones farmaceuticas que los contienen y su uso para el tratamiento de ansiedad, depresion y trastornos del sueno.
TW200612962A (en) Estriol and estetrol prodrugs
MX2011011618A (es) Agentes terapeuticos 713.
MX2010001370A (es) Composiciones que comprenden agonista del receptor glucocorticoide disociado para tratar o controlar inflamacion del segmento anterior.
PE20110402A1 (es) Derivados de estratieno que comprende biososteros heterociclicos para el anillo fenolico a
UY28334A1 (es) Composicion que comprende antagonistas de receptores de progesterona y antiestrógenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas.
UY26665A1 (es) Estratrienos sustituidos como estrógenos selectivamente activos
CL2007002788A1 (es) Un compuesto derivado de (cis)-8-fluorodibenzo[b,f]pirido[1,2-d]oxazepin-1-amina, modulador de los receptores de progesterona; composicion farmaceutica; y uso como anticonceptivo, para la terapia de reemplazo hormonal o para el tratamiento de un tras
PE20090152A1 (es) Combinacion farmaceutica que comprende un antagonista del receptor de progesterona y un antiestrogeno
AR069188A1 (es) Compociones y metodos para tratar una hemorragia uterina disfuncional
PE20070406A1 (es) Aciltriptofanoles como antagonistas del receptor de la hormona foliculo estimulante (fsh)
AR072781A1 (es) Composiciones que comprenden cdb-4124 y metodos de contracepcion masculina

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed